Menu
Washingtoner
  • Home
  • Business
  • Books
  • Technology
  • Endpoint Management
  • Software
  • Health
  • Transportation
  • Lifestyle
Washingtoner

Global Myeloproliferative Neoplasm Drugs Market to Surpass US$ 10,966.8 Million by 2027, Says Coherent Market Insights (CMI)
Washingtoner/10101104

Trending...
  • Tacoma: Community Invited to Learn About Equity Index Tool on April 29
  • Charles Arnell joins Fast Mobile Home Loans
  • Spokane: Duplex Structure Fire
SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global myeloproliferative neoplasm drugs market is estimated to be valued at US$ 8,379.5 million in 2020 and is expected to exhibit a CAGR of 3.9% over the forecast period (2020-2027).

Key Trends and Analysis:

The increasing incidence of myeloproliferative neoplasm is expected to drive growth of the global myeloproliferative neoplasm drugs market over the forecast period. According to the National Organization for Rare Disorders (NORD) 2020, men are more likely to be affected than women with polycythemia vera and this disorder is expected to affect around two people per 100,000 in the general population globally.

Moreover, the increasing number of pipeline products for the treatment of myeloproliferative neoplasm is expected to fuel growth of the global myeloproliferative neoplasm drugs market in the near future. For instance, on January 7, 2021, PharmaEssentia Corporation, a company focusing on research and development in biopharmaceutical industry, announced the initiation of investigational study phase 3 pivotal clinical trial of SURPASS ET, [Ropeginterferon Alfa-2b (P1101)]. SURPASS ET is a novel mono-pegylated proline interferon under evaluation for the treatment of the essential thrombocythemia (ET) type of myeloproliferative neoplasm (MPNs).

Among regions, North America is expected to register highest growth rate, owing to increasing number of pipeline products for the treatment of myeloproliferative neoplasm. For instance, in December 2020, AbbVie Inc. announced new data from the Phase 2 CAPTIVATE (PCYC-1142) clinical trial, evaluating IMBRUVICA (ibrutinib) in combination with VENCLEXTA/VENCLYXTO (venetoclax) in previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), during an oral presentation session at the virtual 2020 American Society of Hematology (ASH) Annual Meeting.

More on Washingtoner
  • Tacoma: Mayor Victoria Woodards on Rollback of Pierce County to Phase 2
  • Bavan M. Holloway Nominated to T-Mobile US Board of Directors
  • Introducing Moxie In The Kitchen: A Free Virtual Cooking Program By Homemade And SCANPAN/GLOBAL Cutlery
  • National Association of Tax Professionals hires new manager of state chapter activity
  • Bidding Now Open for the NFT Artwork For Sale Entitled 'The Sunrise' by Digital Artist, Kevin Douglas Wright

Request Sample Copy of this Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/930

Key Market Takeaways:


The global myeloproliferative neoplasm drugs market is expected to exhibit a CAGR of 3.9% over the forecast period, as key players are focusing on strategies such as mergers and acquisitions in order to strengthen their position in the market. For Instance, in February 2020, F. Hoffmann-La Roche AG completely acquired Promedior, Inc., a clinical stage biotechnology company. As a result of this acquisition, F. Hoffmann-La Roche AG would obtain full rights to Promedior's entire portfolio of molecules for serious fibrotic diseases, including PRM-151.

Competitive Landscape:

Key players operating in the global myeloproliferative neoplasm drugs market include Novartis International AG, PharmaEssentia Corporation, Bristol - Myers Squibb, Pfizer, Inc., Takeda Pharmaceutical Company Limited, Incyte, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Gamida Cell, Sierra Oncology, Inc., CTI BioPharma Corp., Imago BioSciences, AbbVie Inc., and Constellation Pharmaceuticals

Buy-Now this Research Report for detailed market insights @
https://www.coherentmarketinsights.com/insight/buy-now/930

Market Segmentation:
  • Global Myeloproliferative Neoplasm Drugs Market, By Drug Class:
    • Demethylation Agents
    • Tyrosine kinase Inhibitor
    • Multikinase Inhibitors
    • JAK2 Inhibitor
    • Others
  • Global Myeloproliferative Neoplasm Drugs Market, By Indication:
    • Ph+ Chronic myelogenous leukemia (CML)
    • Ph- Myeloproliferative Neoplasms (MPNs)
      • Myelofibrosis (MF)
      • Polycythemia Vera (PV)
      • Essential thrombocythemia (ET)
  • Global Myeloproliferative Neoplasm Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Myeloproliferative Neoplasm Drugs Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country/Region:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa

Related Market Intelligence Reports:

More on Washingtoner
  • OS-Independent, License-Free On-Chip SAE J1939 Protocol Stack for Embedded, Linux, and Windows Systems
  • International Institute of Forecasters Announces the Appointment of Two New Board Members
  • PermaTherm Launches New Website
  • Heather Dixon Srigley joins SagaCity Media as its first Chief Brand Officer
  • Forrest Richardson and Jeff Danner Announce New Golf Design Firm

Urinary Incontinence Treatment Drugs Market, by Incontinence Type (Urge Incontinence, Stress Incontinence, Over-flow Incontinence, Mixed Incontinence, and Other Type), by Drug Class (Anticholinergic/Antispasmodic Agents, Skeletal Muscle Relaxants, Antidepressants, Alpha Blockers, Topical Estrogens, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Read-more: https://www.coherentmarketinsights.com/market-insight/urinary-incontinence-treatment-drugs-market-4400

About Us:

Coherent Market Insights
is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.stats
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • FuseFX Acquires Australia-based Rising Sun Pictures
  • Nisk Real Estate Launches South Florida Brokerage
  • Spokane Parks Windstorm Restoration Plans Underway
  • Fortive Recommends Rejection by Shareholders of the Mini-Tender Offer by TRC Capital Investment Corporation
  • Charles Arnell joins Fast Mobile Home Loans
  • Tacoma: Community Invited to Learn About Equity Index Tool on April 29
  • Davis Wright Tremaine Adds More In-House Leadership from Tech Industry to Silicon Valley Office
  • Daminion Has Made Its Digital Asset Management System Even More Efficient for Marketing and Communications Departments
  • BEAR Technologies Receives SOC 2 Type II Attestation
  • Spokane: Stolen Bikes Recovered
  • Screening Eagle Welcomes Darren Burford as New Chief Sales Officer
  • Fund Street Technologies' Brand, One Park Financial Earns "Best Places To Work" Award by South Florida Business Journal
  • Julia Hair Spring Sale Up To 46% Off With Buy Now Pay Later
  • CB Insights Again Names AI.Reverie a Top 100 AI Startup
  • Global Recurrent Glioblastoma Multiforme Treatment Market to Reach Up To US$ 560.9 Million by 2027, Says Coherent Market Insights (CMI)
  • LumiThera Announces Top Line Data in the European Multi-Center, LIGHTSITE II Clinical Study to Treat Dry Age-Related Macular Degeneration
  • Ismail Sirdah's Helpful Tips For Selling Event Ticket Online
  • Spokane: Flags to Remain Lowered For Congressman Alcee Hastings
  • Spokane: Virtual Spring Compost Fair Planned
  • East Spokane House Fire
_catLbl0 _catLbl1

Popular on Washingtoner

  • Evolve IP's Microsoft Teams Direct Routing Solution With Integrated Contact Center Recognized In Multiple Gartner Research Papers
  • Paradies Lagardère First to Launch MishiPay's Scan, Pay & Go Technology in U.S. Airports
  • Best Last Tax Refunder Sale 2021-Hurela Mall
  • Spokane: Indian Canyon Golf Course Opens Friday, March 26, 2021
  • Syxsense Releases Virtual Machine Host Patching Job Template
  • EndBrainCancer Initiative Continues Its Expansion
  • Sandline Global Adds Top Industry Talent: Brandon Mack, Esq. Joins as SVP of Analytics and Global Advisory
  • Spokane: When the Power's Out, Everybody Stops
  • Air Force Veteran Joins Prominent Haddonfield Real Estate Agency
  • Tacoma: City Council Adopts Resolution Denouncing Anti-Asian American and Pacific Islander Sentiment

Similar on Washingtoner

  • JetQuay Launches Private Swab Test Facility, Halves Custom Clearance Timing
  • Bavan M. Holloway Nominated to T-Mobile US Board of Directors
  • Introducing Moxie In The Kitchen: A Free Virtual Cooking Program By Homemade And SCANPAN/GLOBAL Cutlery
  • Bidding Now Open for the NFT Artwork For Sale Entitled 'The Sunrise' by Digital Artist, Kevin Douglas Wright
  • PermaTherm Launches New Website
  • International Institute of Forecasters Announces the Appointment of Two New Board Members
  • Heather Dixon Srigley joins SagaCity Media as its first Chief Brand Officer
  • Contracting Resources Group Awarded ISO 9001:2015 Certification for Quality Management System
  • NuriFlex’s Service Scope to Be Broadened to Include a Telemedicine Platform for the Universal Health Coverage Project in Cameroon
  • PEMCO Mutual Insurance Welcomes New Director, Data Governance
Copyright © 2021 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute